Health Condition 1: F329- Major depressive disorder, singleepisode, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Sponsors
AIIMS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-55 years of either gender. 2. Patients clinically diagnosed with depression. 3. Patients on treatment with antidepressants (Going to start or taking antidepressants for less than 15 days) 4. Patients with (at least for 3 months) and without concomitant treatment of ACEI/ARBs 5. Patients who can read and understand Hindi or English. 6. Patients willing to participate and give consent
Exclusion criteria
Exclusion criteria: 1. Pregnant or seeking pregnancy, lactating women. 2. Patients clinically diagnosed with any other neurological or psychiatric disorders (e.g. Alzheimer disease, Parkinson disease, Multiple sclerosis etc.) At the time of enrolment. 3. Patients suffering from any other chronic disease (like peptic ulcer, respiratory disease, liver disease, diabetes, any malignancy) apart from cardiovascular conditions (hypertension, ischemic heart disease, heart failure) which are not in acute/severe/decompensated state. 4. Patients on medications other than antidepressants and ACEI/ARBs, which are having potential to alter RAAS system biomarkers and antidepressant treatment response (e.g. Beta blockers, diuretics, direct renin inhibitors)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To find out the antidepressant treatment response by using clinical depression rating scales in subjects with ACEI/ARBs along with antidepressant vs. Antidepressants alone Using HDRS scoreTimepoint: HDRS SCORE at baseline and at 6 weeks follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| To correlate the antidepressant treatment response with expression of blood biomarkers related to RAAS and depression (BDNF, Cortisol) and their genetic expression in peripheral blood mononuclear cells of subjects with ACEI/ARBs along with antidepressant vs. Antidepressants alone. 2. To assess the safety of ACEI/ARBs along with antidepressant vs. Antidepressants alone in subjects with depression through routine lab tests (RFT, LFT, lipid profile) Timepoint: ELISA test for RAAS related biomarkers will be done at baseline and at 6-week follow-up. Gene expression analysis will be done at baseline in consecutive subjects till at least 20 subjects are obtained in each of the groups. Blood test( LFT, KFT, LIPID PROFILE) at baseline | — |
Countries
India
Contacts
Public ContactSudhir Chandra Sarangi
All India Institute of Medical Sciences, New Delhi
Outcome results
None listed